发明名称 Thieno-pyrimidines, useful as potassium channel inhibitors
摘要 The present invention provides compounds of formula (I): (Formula (I); wherein A, R1, R2, R3I, V, X, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof.
申请公布号 US9290511(B2) 申请公布日期 2016.03.22
申请号 US201214358722 申请日期 2012.11.15
申请人 Xention Limited 发明人 Madge David;Chan Fiona;John Derek Edward;Edwards Simon D.;Blunt Richard;Hartzoulakis Basil;Brown Lindsay
分类号 C07D495/04;A61K31/519;A61P9/06;C07D491/048 主分类号 C07D495/04
代理机构 Baker Botts L.L.P. 代理人 Baker Botts L.L.P.
主权项 1. A compound of formula (I)or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein: A is S; X is N; V is CR3III; Z is N; R1 is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; R2 is selected from H, halo, —CN, trifluoromethyl, optionally substituted alkyl, optionally substituted alkoxy, NR4R5, —NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R′, —CONR4R5, —CO2R7, optionally substituted oxazolinyl, —SR14, —S(O)R14 and —S(O)2R14; R31 is (NRaRb)-J; R3111 is selected from H, halo, —CN, trifluoromethyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heterocycloalkoxy, optionally substituted heterocycloalkylalkyl, —NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5, optionally substituted -alkylene-CONR4R5, —CO2R7, —NR10R11, —C≡C-J, optionally substituted cycloalkyl-J and —(NRcRd)-J; wherein Ra and Rb are linked to form an optionally substituted 4 to 7 membered heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1-2alkylene, —NR6—, —O—, or —S(O)z—, wherein the optionally bridged, optionally substituted heterocycloalkyl ring is selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydro-1,3-oxazinyl, hexahydropyrimidinyl, 1,4-thiazanyl, azepanyl, 1,4-oxaazepanyl, and 1,4-thieazepanyl; wherein Rc and Rd are linked to form an optionally substituted 4 to 7 membered heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1-2alkylene, —NR6—, —O—, or —S(O)z—; J is —(CR12R13)q-L-M-W,wherein q is 0, 1 or 2; L is —O—; M is —(CR12R13)t; t is 0, 1, 2or 3; W is selected from the group consisting of optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl and —NR8R9, wherein when W is optionally substituted cycloalkyl it may optionally be bridged by a bond or optionally substituted C1-2alkylene, and wherein when W is optionally substituted heterocycloalkyl it may optionally be bridged by a bond, optionally substituted C1-2alkylene, —NR6—, —O—, or —S(O)z—; z is 0, 1 or 2; R4 and R5 are, at each instance, independently selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl, or are linked to form an optionally substituted heterocycloalkyl; R6 and R7 are, at each instance, independently selected from H and optionally substituted alkyl, or are linked to form an optionally substituted heterocycloalkyl; R8 and R9 are, at each instance, independently selected from optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; R10 and R11 are, at each instance, independently selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; R12 and R13 are, at each instance, independently selected from H, hydroxy, and optionally substituted alkyl, or may be linked to form an optionally substituted cycloalkyl ring, or may together form ═O; and R14 is optionally substituted alkyl, wherein the optional substituents are independently selected from halo, trihalomethyl, trihaloethyl, trihalomethoxy, trihaloethoxy, —OH, —NO2, —CN, —CO2H, —CO2C1-6alkyl, —SO3H, —SOC1-6alkyl, —SO2C1-6alkyl, —NHSO2C1-6alkyl, —NC1-6alkylSO2C1-6alkyl, —SO2NH2, —SO2NHC1-6alkyl, —SO2N(C1-6alkyl)2, —NHSO2NH2, —NHSO2NHC1-6alkyl, —NHSO2N(C1-6alkyl)2, —NC1-6alkylSO2NH2, —NC1-6alkylSO2NHC1-6alkyl, —NC1-6alkylSO2N(C1-6alkyl)2, —C(═O)H, —C(═O)C1-6alkyl, —NHC(═O)C1-6alkyl, —NC1-6alkylC(═O)C1-6alkyl, C1-6alkylenedioxy, ═O, —N(C1-6alkyl)2, —C(═O)NH2, —C(═O)NHC1-6alkyl, —C(═O)N(C1-6alkyl)2, —NHC(═O)NH2, —NHC(═O)NHC1-6alkyl, —NHC(═O)N(C1-6alkyl)2, —NC1-6alkylC(═O)NH2, —NC1-6alkylC(═O)NHC1-6alkyl, —NC1-6alkyl C(═O)N(C1-6alkyl)2, —C(═NH)NH2, —C(═NH)NHC1-6alkyl, —C(═NH)N(C1-6alkyl)2, —C(═NC1-6alkyl)NH2, —C(═NC1-6alkyl)NHC1-6alkyl, —C(═NC1-6alkyl)N(C1-6alkyl)2, —C1-6alkyl, —C3-6cycloalkyl, —C3-6heterocycloalkyl, 2-imidazolidinon-3-yl, 1-C1-6alkyl-2-imidazolidinon-3-yl, C1-6alkylC3-6heterocycloalkyl, aryl, haloaryl, C1-6alkoxyaryl, —C1-6alkylene-NHSO2C1-6alkyl, —C1-6alkylene-NC1-6alkylSO2C1-6alkyl, —C1-6alkylene-SO2NH2, —C1-6alkylene-SO2NHC1-6alkyl, —C1-6alkylene-SO2N(C1-6alkyl)2, —ZtH, —Zt—C1-6alkyl, —C1-6alkylene-ZtH, —Zt—C3-6cycloalkyl, or —C(═O)NHC1-6alkylene-ZtH wherein Zt is independently O, S, NH or N(C1-6alkyl).
地址 Cambridge GB